NCT04061863View on ClinicalTrials.gov

Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

April 30, 2022

Study Completion Date

December 31, 2022

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Nivolumab

Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks

Trial Locations (1)

13620

Seoul National University Bundang Hospital, Seongnam

Sponsors

Collaborators (1)

Ono pharmaceutical Korea
All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Korean Cancer Study Group (KCSG)

UNKNOWN

collaborator

Eisai Korea Inc.

INDUSTRY

collaborator

Ono pharmaceutical Korea

UNKNOWN

lead

Seoul National University Hospital

OTHER